80
Participants
Start Date
July 10, 2023
Primary Completion Date
June 30, 2025
Study Completion Date
December 31, 2025
TQB3454 Tablets
TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor
RECRUITING
Shanghai Tongren Hospital, Shanghai
RECRUITING
Huashan Hospital affiliated to Fudan University, Shanghai
RECRUITING
Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai
RECRUITING
Shanghai Sixth People's Hospital, Shanghai
RECRUITING
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai
RECRUITING
Wuxi People's Hospital, Wuxi
RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Affiliated Hospital of Binzhou Medical College, Binzhou
RECRUITING
Yantai Mountain Hospital, Yantai
RECRUITING
Yantai Yuhuangding Hospital, Yantai
RECRUITING
Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin
RECRUITING
Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
West China Hospital, Sichuan University, Chengdu
RECRUITING
Cangzhou people's Hospital, Cangzhou
RECRUITING
The Affiliated Hospital of Chengde Medical College, Chengde
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY